Scope
This ACG guideline links genetic assessment of adenomatous polyposis to lifelong, phenotype-directed cancer prevention. The selected recommendations cover familial adenomatous polyposis (FAP), attenuated FAP, biallelic MUTYH-associated polyposis (MAP) and colonic polyposis of unknown aetiology, including surveillance after surgery. Many decisions rely on low-certainty evidence and specialist multidisciplinary judgement.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Recognise the syndrome and interpret genetic testing
- Suspect hereditary adenomatous polyposis with at least 10 cumulative colorectal adenomas, especially with early onset or relevant cancer history. Obtain a detailed personal and at least three-generation family history; absence of family history does not exclude a hereditary syndrome. [1]
- ACG recommends multigene panel testing with at least 20 cumulative lifetime adenomatous colorectal polyps, and conditionally suggests it with 10–19. Both recommendations have low-certainty evidence; discuss age, personal/family history, likely yield and patient preferences. [1]
- Recommend germline APC testing for desmoid tumour, cribriform morular thyroid carcinoma, bilateral and/or multifocal congenital hypertrophy of retinal pigment epithelium, or hepatoblastoma (strong recommendation, low-certainty evidence). [1]
- When a familial pathogenic variant is identified, offer cascade testing: relatives carrying it need syndrome-specific management, whereas those testing negative for that familial variant return to average-risk screening. A relative declining testing should be managed as positive; an uninformative result when the affected relative was never tested is not a true negative. [1]
- A variant of uncertain significance should generally not alter care; use personal and family history. Reassess older or incomplete negative panels and changed cancer histories. With at least 20 adenomas and uninformative panel testing, consider specialist evaluation for APC mosaicism case by case. [1]
Colorectal surveillance and resection
- For asymptomatic classic FAP carriers or untested people at risk, begin colonoscopy by age 10–15 years. For attenuated FAP or MAP carriers or untested people at risk, begin by 18–20 years. Continue every 1–3 years according to polyp number, size and histology. [1]
- Document estimated polyp numbers and size ranges separately for colon and rectum at baseline and follow-up. Resect colorectal polyps at least 10 mm when they lack features of submucosal invasion, and excise polyps at least 4 mm where feasible. [1]
- In adenomatous polyposis, invasive colorectal cancer, at least 1,000 polyps, unresectable advanced adenomas or symptoms from significant polyp burden are absolute surgical indications. Multiple high-grade or large adenomas, inadequate endoscopic surveillance and increasing burden are relative indications. Individualise timing with an experienced multidisciplinary team. [1]
- For FAP requiring surgery with more than 20 rectal adenomas, conditionally favour proctocolectomy with ileal pouch–anal anastomosis when the patient prioritises reduced subsequent rectal surgery/cancer over function. With rectal-sparing FAP and at most 20 rectal adenomas, conditionally favour colectomy with ileorectal anastomosis for quality of life. Evidence is very low certainty; individualise the choice. [1]
- After ileal pouch–anal or ileorectal anastomosis, annual lower endoscopy is suggested, with shorter intervals for numerous, large or advanced adenomas. Consider further surgery when polyp burden cannot be controlled endoscopically, with or without chemoprevention. [1]
- Do not replace indicated colectomy with chemoprevention (strong recommendation, moderate-certainty evidence). Sulindac or celecoxib may be considered individually as adjuncts to endoscopic surveillance, but whether they reduce cancer or surgery is uncertain; discuss risks and benefits. [1]
Upper gastrointestinal surveillance and intervention
- For FAP, attenuated FAP and MAP, conditionally offer upper endoscopic surveillance that visualises the duodenal papilla. Begin at age 20–25 years in FAP/attenuated FAP and 30–35 years in MAP, or earlier according to family history. The recommendation has low-certainty evidence. [1]
- In FAP, attenuated FAP or MAP, suggested duodenal surveillance intervals by Spigelman stage are: stage 0, every 3–5 years; I, every 3 years; II, every 2–3 years; III, every 6–12 months; IV, every 3–6 months. This is conditional, with low-certainty evidence; document the score components. [1]
- For duodenal adenomas larger than 10 mm or any high-grade dysplasia, conditionally favour therapeutic intervention over surveillance alone. Choose endoscopic or surgical resection according to duodenal/ampullary burden, preferences and access to experienced therapeutic endoscopy (low-certainty evidence). [1]
- In adenomatous polyposis without an indication for duodenectomy, conditionally favour endoscopic over surgical ampullectomy for an ampullary adenoma at least 10 mm, with high-grade dysplasia or causing pancreatobiliary symptoms, provided intraductal extension is not greater than 10 mm. Evidence is very low certainty. [1]
- For gastric polyposis in FAP, attenuated FAP or MAP, conditionally suggest endoscopic resection of all antral polyps, proximal polypoid mounds, polyps at least 10 mm, gastric adenomas and white mucosal patches. Evidence is very low certainty; high-risk gastric disease warrants an experienced endoscopic and surgical centre. [1]
- After pancreas-sparing duodenectomy or pancreaticoduodenectomy, continue endoscopic surveillance of the anastomoses and adjacent jejunal limbs; starting at 2 years is reasonable, with subsequent intervals guided by polyp burden and pathology. After gastrectomy, continue duodenal surveillance according to Spigelman stage. [1]
Selected extracolonic surveillance
- For FAP or attenuated FAP, consider baseline thyroid ultrasound by age 18. If normal, consider repeating in 5 years; existing or new nodules need shorter intervals guided by growth and imaging features. [1]
- In FAP, attenuated FAP or MAP with a palpable abdominal mass, obtain abdominal/pelvic cross-sectional imaging for desmoid disease. Consider preoperative imaging when desmoids occur in the family; do not use routine cross-sectional screening for desmoids or adrenal adenomas. [1]
- Counsel parents of children carrying an APC pathogenic variant about hepatoblastoma risk and the lack of evidence supporting screening. Screening may be considered individually after an informed discussion. [1]
Unknown cause and rarer genetic syndromes
- At least 10 cumulative lifetime colorectal adenomas with negative multigene panel testing meet the guideline definition of colonic polyposis of unknown aetiology (CPUE). A negative panel does not remove the need to assess and follow the polyp phenotype. [1]
- In CPUE with at least 20 adenomas, perform colonoscopy every 1–3 years, individualised by polyp size, number and histology. Colorectal cancer or endoscopically unmanageable polyposis indicates colectomy. [1]
- For CPUE, perform baseline upper endoscopy at diagnosis, then guide surveillance by gastric, duodenal and ampullary findings. With at least 20 adenomas, also offer baseline thyroid ultrasound and consider follow-up using the FAP/attenuated-FAP approach. [1]
- Refer families with rarer adenomatous polyposis syndromes to centres with multidisciplinary expertise. The limited and selected evidence does not establish their complete cancer spectrum or a definitive surveillance pathway. [1]
Limitations and use
- This selected summary does not supply the complete genetic panel, gene-specific counselling, Spigelman scoring criteria, procedural techniques or drug dosing and safety protocols.
- Most surveillance and intervention decisions draw on observational specialist-centre evidence. Timing must be adapted to phenotype, symptoms, surgical risk and available expertise.
- Chemoprevention does not substitute for surveillance or indicated surgery. Rare-syndrome surveillance and family management need specialist genetic assessment rather than automatic application of FAP schedules.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Diagnosis & Management of Adenomatous Colorectal Polyposis Syndromes
Selected recommendation material consulted
Publication details
- Issuing organisation
- ACG
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.